Canaccord initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $20 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics initiated with a Buy at BofA
- Largest borrow rate increases among liquid names
- Candel Therapeutics provides corporate update, highlights momentum
- Candel Therapeutics Highlights Pipeline Progress and Stability
- Candel Therapeutics Inc call volume above normal and directionally bullish